98%
921
2 minutes
20
The 4th Davos Declaration was developed during the Global Allergy Forum in Davos which aimed to elevate the care of patients with atopic dermatitis (AD) by uniting experts and stakeholders. The forum addressed the high prevalence of AD, with a strategic focus on advancing research, treatment, and management to meet the evolving challenges in the field. This multidisciplinary forum brought together top leaders from research, clinical practice, policy, and patient advocacy to discuss the critical aspects of AD, including neuroimmunology, environmental factors, comorbidities, and breakthroughs in prevention, diagnosis, and treatment. The discussions were geared towards fostering a collaborative approach to integrate these advancements into practical, patient-centric care. The forum underlined the mounting burden of AD, attributing it to significant environmental and lifestyle changes. It acknowledged the progress in understanding AD and in developing targeted therapies but recognized a gap in translating these innovations into clinical practice. Emphasis was placed on the need for enhanced awareness, education, and stakeholder engagement to address this gap effectively and to consider environmental and lifestyle factors in a comprehensive disease management strategy. The 4th Davos Declaration marks a significant milestone in the journey to improve care for people with AD. By promoting a holistic approach that combines research, education, and clinical application, the Forum sets a roadmap for stakeholders to collaborate to improve patient outcomes in AD, reflecting a commitment to adapt and respond to the dynamic challenges of AD in a changing world.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1111/all.16247 | DOI Listing |
BMJ Open
July 2025
Department of Dermatology, Vrije Universiteit Brussel, Universitair Ziekenhuis Brussels, Jette, Belgium.
Introduction: Atopic dermatitis (AD) is a chronic, relapsing, heterogeneous skin disease affecting 2%-7% of adults, with roughly 30% having moderate-to-severe disease. AD symptoms, like intense itching and skin pain, carry a substantial disease burden that negatively impacts patients' quality of life (QoL) and psychosocial well-being. Lebrikizumab is a novel, high-affinity monoclonal antibody that selectively binds to and neutralises interleukin-13 with high potency.
View Article and Find Full Text PDFJ Eur Acad Dermatol Venereol
September 2025
St John's Institute of Dermatology, King's College London, London, UK.
The evidence- and consensus-based living guideline on atopic eczema was developed in accordance with the EuroGuiDerm Guideline and Consensus Statement Development Manual. The original EuroGuiDerm Guideline on atopic eczema was published in June 2022. Since then, the part of the guideline dealing with systemic therapy has been updated twice.
View Article and Find Full Text PDFPharmaceuticals (Basel)
November 2024
AO Research Institute Davos, 7270 Davos, Switzerland.
Allergy
October 2024
Christine Kühne-Center for Allergy Research and Education (CK-CARE), Medicine Campus, Davos, Switzerland.
Chimia (Aarau)
December 2021
CSEM Centre Suisse d'Electronique et de Microtechnique SA, Landquart SA, Bahnhofstr. 1, CH-7302 Landquart;, Email:
After last year's successful online symposium, the 4 edition of the Swiss Symposium in POC Diagnostics gathered more than 150 participants from medicine, industry and science as well as from different European countries to meet at the Davos Conference Center for an exciting program with 13 expert speakers, a poster session and a product & technology exhibition. The mandatory COVID-certificate to access the event has allowed people to meet (again at last!), network and share their views and success stories in the field of POC Diagnostics that continues to be propelled by digitalization, new technological possibilities, user needs and the COVID-19 pandemic.
View Article and Find Full Text PDF